Silvia Mappa

686 total citations
27 papers, 442 citations indexed

About

Silvia Mappa is a scholar working on Pathology and Forensic Medicine, Hematology and Molecular Biology. According to data from OpenAlex, Silvia Mappa has authored 27 papers receiving a total of 442 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Pathology and Forensic Medicine, 9 papers in Hematology and 8 papers in Molecular Biology. Recurrent topics in Silvia Mappa's work include Lymphoma Diagnosis and Treatment (14 papers), Acute Myeloid Leukemia Research (6 papers) and Chronic Lymphocytic Leukemia Research (5 papers). Silvia Mappa is often cited by papers focused on Lymphoma Diagnosis and Treatment (14 papers), Acute Myeloid Leukemia Research (6 papers) and Chronic Lymphocytic Leukemia Research (5 papers). Silvia Mappa collaborates with scholars based in Italy, United States and United Kingdom. Silvia Mappa's co-authors include Andrés J.M. Ferreri, Silvia Govi, Maurilio Ponzoni, Claudio Doglioni, Elisa Pasini, Riccardo Dolcetti, Caterina Stelitano, Renato Alterini, Antonio Giordano Resti and Letterio S. Politi and has published in prestigious journals such as Journal of Clinical Oncology, Blood and European Journal of Cancer.

In The Last Decade

Silvia Mappa

27 papers receiving 437 citations

Peers

Countries citing papers authored by Silvia Mappa

Since Specialization

Citations

This map shows the geographic impact of Silvia Mappa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Silvia Mappa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Silvia Mappa more than expected).

Fields of papers citing papers by Silvia Mappa

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Silvia Mappa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Silvia Mappa. The network helps show where Silvia Mappa may publish in the future.

Co-authorship network of co-authors of Silvia Mappa

This figure shows the co-authorship network connecting the top 25 collaborators of Silvia Mappa. A scholar is included among the top collaborators of Silvia Mappa based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Silvia Mappa. Silvia Mappa is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Loncastuximab Tesirine Versus Polatuzumab Vedotin Plus Bendamustine and Rituximab in Relapsed/Refractory DLBCL After ≥ 2 Lines of Therapy: Matching-Adjusted Indirect Comparison 2025 ·Advances in Therapy ·Koo Wilson, Francesca Chiodi, (unknown), Zalmaï Hakimi, Victoria Ward, (unknown), Daniel Eriksson, Silvia Mappa	1
2	CO143 Loncastuximab Tesirine Versus Glofitamab for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma After Two or More Lines of Systemic Therapy: A Matching-Adjusted Indirect Comparison 2024 ·Value in Health ·Koo Wilson, Francesca Chiodi, (unknown), Zalmaï Hakimi, Silvia Mappa, T.G. Crowe, (unknown), Daniel Eriksson, Gabriel Lenz	1
3	Trial in Progress: Randomized, Double-Blind, Placebo-Controlled Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients with Cold Agglutinin Disease (CASCADE) 2022 ·Blood ·Bernd Jilma, Eloy Roman, Yutaka Ueda, Silvia Mappa, Johan Szamosi, (unknown), (unknown)	1
4	Phase 2 study of avatrombopag in Japanese patients with chronic liver disease and thrombocytopenia 2022 ·Hepatology Research ·Yuichiro Eguchi, Hirokazu Takahashi, Silvia Mappa, Elena Santagostino	3
5	Treatment of MALT lymphoma of the conjunctiva with intralesional rituximab supplemented with autologous serum 2020 ·Blood Advances ·Andrés J.M. Ferreri, Marianna Sassone, Elisabetta Miserocchi, Silvia Govi, (unknown), (unknown), Silvia Mappa, Luca Arcaini, Francesco Zaja, Giuseppe Todeschini, Donato Mannina, Teresa Calimeri, Salvatore Perrone, Maurilio Ponzoni, Giulio Modorati	9
6	Phase II study of lower-dose pracinostat plus azacitidine safety and efficacy in patients with high/very high-risk myelodysplastic syndromes. 2020 ·Journal of Clinical Oncology ·Ehab Atallah, Samer K. Khaled, Brenda Cooper, Erica D. Warlick, David A. Ramies, Joanne Li, (unknown), Silvia Mappa, Michael Keng	3
7	A Phase 3 Randomized Study (PRIMULA) of the Epigenetic Combination of Pracinostat, a Pan-Histone Deacetylase (HDAC) Inhibitor, with Azacitidine (AZA) in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Intensive Chemotherapy (IC) 2019 ·Blood ·Guillermo Garcia‐Manero, Maciej Kaźmierczak, Chun Yew Fong, Pau Montesinos, Adriano Venditti, Silvia Mappa, (unknown), Lionel Adès	5
8	Planned Interim Analysis of a Phase 2 Study Evaluating the Combination of Pracinostat, a Histone Deacetylase Inhibitor (HDACi), and Azacitidine in Patients with High/Very High-Risk Myelodysplastic Syndrome (MDS) 2018 ·Blood ·Michael Keng, Samer K. Khaled, Brenda Cooper, Erica D. Warlick, David A. Ramies, Silvia Mappa, Ehab Atallah	2
9	Phase 2A Study of Copanlisib, a Novel PI3K Inhibitor, in Patients with Indolent Lymphoma 2014 ·Blood ·Martin Dreyling, David Cunningham, Krimo Bouabdallah, Sarit Assouline, Eric Van Den Neste, Umberto Vitolo, Marius Giurescu, Silvia Mappa, (unknown), Barrett H. Childs, Franck Morschhauser	16
10	The clinical features, management and prognosis of primary and secondary indolent lymphoma of the bone: a retrospective study of the International Extranodal Lymphoma Study Group (IELSG #14 study) 2013 ·Leukemia & lymphoma ·Silvia Govi, David Christie, Silvia Mappa, (unknown), (unknown), Carlo Messina, Elías Gracia, David Porter, John Radford, Dae Seog Heo, (unknown), Barbara Pro, (unknown), Nick Pavlakis, Emanuele Zucca, Mary Gospodarowicz, Andrés J.M. Ferreri, (unknown)	11
11	Preliminary Results Of a Phase II Study Of Single Agent Bay 80-6946, a Novel PI3K Inhibitor, In Patients With Relapsed/Refractory, Indolent Or Aggressive Lymphoma 2013 ·Blood ·Martin Dreyling, Franck Morschhauser, Dominique Bron, Krimo Bouabdallah, Umberto Vitolo, Kim Linton, Eric Van Den Neste, Silvia Mappa, Marius Giurescu, Barrett H. Childs, Pier Luigi Zinzani	32
12	A Reappraisal of the Diagnostic and Therapeutic Management of Uncommon Histologies of Primary Ocular Adnexal Lymphoma 2013 ·The Oncologist ·Maurilio Ponzoni, Silvia Govi, Giada Licata, Silvia Mappa, Antonio Giordano Resti, Letterio S. Politi, Lorenzo Spagnuolo, (unknown), Claudio Doglioni, Andrés J.M. Ferreri	27
13	Chlamydophila Psittaci Eradication With Doxycycline As First-Line Targeted Therapy for Ocular Adnexae Lymphoma: Final Results of an International Phase II Trial 2012 ·Journal of Clinical Oncology ·Andrés J.M. Ferreri, Silvia Govi, Elisa Pasini, Silvia Mappa, Francesco Bertoni, Francesco Zaja, Carlos Montalbán, Caterina Stelitano, María Elena Cabrera, Antonio Giordano Resti, Letterio S. Politi, Claudio Doglioni, Franco Cavalli, Emanuele Zucca, Maurilio Ponzoni, Riccardo Dolcetti	117
14	Contrast enhanced (ce) CT in staging and end-of-treatment evaluation in lymphoma in the FDG PET/CT era: A need or a habit? 2012 ·Margarita Kirienko, Luca Guerra, Silvia Bolis, (unknown), Davide Ippolito, Paola Mapelli, Federico Fallanca, Silvia Mappa, Cristina Messa	1
15	Safety and Activity of Intensive Short-Term Chemoimmunotherapy in HIV-Positive (HIV+) Patients (pts) with Burkitt Lymphoma (BL) 2011 ·Blood ·(unknown), Giovanni Donadoni, Alessandro Re, Michele Spina, Chiara Cattaneo, Luca Fumagalli, Silvia Mappa, Silvia Govi, Giuseppe Rossi, Umberto Tirelli, Andrés JM Ferreri	1
16	Final Results of a Multicenter Phase II Trial with Translational Elements to Investigate the Possible Infective Causes of Ocular Adnexal Marginal Zone B-Cell Lymphoma (OAMZL) with Particular Reference to Chlamydia Species and the Efficacy of Doxycycline As First-Line Lymphoma Treatment (the IELSG#27 TRIAL) 2011 ·Blood ·Silvia Govi, Riccardo Dolcetti, Maurilio Ponzoni, Elisa Pasini, Silvia Mappa, (unknown), Claudio Doglioni, Francesco Bertoni, Francesco Zaja, Carlos Montalbán, Caterina Stelitano, María Elena Cabrera, Franco Cavalli, Emanuele Zucca, Andrés J.M. Ferreri	3
17	A short low‐dose imatinib trial allows rapid identification of responsive patients in hypereosinophilic syndromes 2009 ·British Journal of Haematology ·Tamara Intermesoli, Federica Delaini, (unknown), Silvia Salmoiraghi, Orietta Spinelli, Vittoria Guerini, Alessandro M. Vannucchi, Silvia Mappa, Giuseppe Rossi, Valentina Rossi, Eros Di Bona, (unknown), Alessandra Carobbio, Alessandro Rambaldi, Tiziano Barbui, Renato Bassan	7
18	Rituximab and chlorambucil as first-line treatment for low-grade ocular adnexal lymphomas 2007 ·Annals of Hematology ·Luigi Rigacci, Luca Nassi, (unknown), Silvia Mappa, Ennio Polito, (unknown), Renato Alterini, Valentina Carrai, Benedetta Puccini, Alberto Bosi	31
19	Liposome‐encapsulated doxorubicin in combination with cyclophosphamide, vincristine, prednisone and rituximab in patients with lymphoma and concurrent cardiac diseases or pre‐treated with anthracyclines 2007 ·Hematological Oncology ·Luigi Rigacci, Silvia Mappa, Luca Nassi, Renato Alterini, Valentina Carrai, (unknown), Alberto Bosi	47
20	Dose-Dense CHOP Plus Rituximab (R-CHOP14) Seems To Overcome, in Large B Cell Lymphoma, the Negative Prognostic Significance of B Cell Origin. 2007 ·Blood ·Luigi Rigacci, Luca Nassi, Simonetta Di Lollo, Benedetta Puccini, (unknown), Silvia Mappa, (unknown), Renato Alterini, Valentina Carrai, Alberto Bosi	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact